Home | Back to newsletter main page
| |
 |
|
January 23, 2012 |
|
CASE CCC IN THE NEWSTherapy Can Add Years to Certain Brain Tumor Patients' Lives Cardiac Risk Higher for Women Getting Radiation UH Case Medical Center Publishes Study on Novel Treatment for Skin Lymphoma MARK YOUR CALENDARSCancer Center Seminar Series: Experimental Therapeutics: The Chronic B-Cell Leukemias
Friday, January 27 Please join us Friday, January 27 for the next Cancer Center Seminar Series where Dr. Michael R. Grever will present Experimental Therapeutics: The Chronic B-Cell Leukemias. Dr. Grever has over 30 years of experience in experimental chemotherapy and drug development for patients with CLL and other hematologic malignancies. He previously served as the Deputy Director of the NCI's Division of Cancer Treatment and the Associate Director of the NCI's Developmental Therapeutics Program, directing the preclinical effort for drug discovery and development of anti-cancer and anti-HIV agents. Dr. Grever performed the initial phase I studies on purine nucleoside analogs in patients with hematologic malignancies, and conducted one of the initial phase II studies of fludarabine in patients with CLL. Dr. Grever remains active in the search for new and effective therapy for CLL. He continues to lead the Phase I Program at OSU, and also provides leadership at a national level, as he recently finished his term as Co-Chair of the NCI's Investigational Drug Branch Steering Committee. He has also served on both RAID and NExT review committees for the NCI. In addition to the U01 funding, he is actively engaged in collaborative team based research involving P01, P50, SPORE, and SCOR projects. His background in pharmacology enabled him to co-lead the program forward with pharmacologically-directed phase I studies of an exciting agent (Flavopiridol). He worked with this agent pre-clinically at the NCI and pursued its clinical development over the past decade. He is now responsible for advising on the preclinical and early clinical development of many new synthetic agents as well as interesting natural products. He has been fortunate to have experience both in preclinical drug discovery and development, as well as the design and conduct of clinical trials leading to FDA approval for several new agents, and shares his experiences with young investigators in his program. Office of Cancer Centers Learning Series WebinarRegister for the next Office of Cancer Centers Learning Series Webinar, An Overview of the FY 2012 Cancer Clinical Investigator Team Leadership Award Application and Review Process for Prospective Applicants, Wednesday, February 1 from 2-3:30 pm. Dr. Jennifer Hayes, the NCI Program Director who oversees the Cancer Clinical Investigator Team Leadership Award Program, will present an overview of the FY 2012 program and discuss the application and application review process. FUNDING OPPORTUNITIESSamuel Waxman Cancer Research Foundation: Individual Research ProposalsThis year, the Samuel Waxman Cancer Research Foundation (SWCRF) will offer several two-year grants to individual investigators. Grantees will have the opportunity to extend their award to three years upon demonstration of successful collaborative efforts with existing members of the SWCRF Institute Without Walls. This RFA will focus on the pursuit of novel compounds, targets, and therapies. Specific themes of interest to the SWCRF include studies that address:
Internal Deadline: February 1 NSF Integrative Graduate Education and Research Traineeship Program (IGERT)The Integrative Graduate Education and Research Traineeship (IGERT) program has been developed to meet the challenges of educating U.S. Ph.D. scientists and engineers with interdisciplinary backgrounds, deep knowledge in chosen disciplines, and technical, professional, and personal skills. The program is intended to establish new models for graduate education and training in a fertile environment for collaborative research that transcends traditional disciplinary boundaries. This is a limited submission opportunity and only 1 application per institution is allowed. Internal Deadline: February 27 New York Academy of Medicine David E. Rogers Fellowship ProgramThe Rogers Fellowship is meant to enrich the educational experiences of medical and dental students through projects that bear on medicine and dentistry as they contribute to the health of communities, and to address the human needs of underserved or disadvantaged patients or populations. The content of the Fellowship might include clinical investigation, public health/epidemiology, health policy analysis, activities linking biomedicine, the social infrastructure and human or community need. Deadline: March 1 American Cancer Society Postdoctoral FellowshipsThe American Cancer Society is accepting applications for postdoctoral fellowships. These awards support the training of researchers who have received a doctoral degree to provide initial funding leading to an independent career in cancer research (including basic, preclinical, clinical, cancer control, psychosocial, behavioral, epidemiology, health services and health policy research). Deadline: April 2 Solving Kids' Cancer Therapeutic Development InitiativeSolving Kids' Cancer is accepting proposals for its Therapeutic Development Initiative (TDI), a strategic program to support the investigation of novel treatments through clinical studies to answer important research questions as quickly, effectively, and economically as possible. Ideal proposals will be those that focus on novel and potentially high-impact therapeutic approaches through well designed clinical studies for neuroblastoma, pediatric CNS tumors and/or sarcomas. Proposals will be accepted on a rolling-basis throughout the year. Support of the Cancer Genome Atlas ProgramSAIC-Frederick is pleased to announce a new solicitation available in support of The Cancer Genome Atlas (TCGA) Program. The Cancer Genome Atlas is a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing. This funding is made available under Congressional appropriated funding and also the American Recovery and Reinvestment Act of 2009 (Recovery Act), Pub. L. No. 111-5. SAIC Frederick hopes to receive proposals from institutions and established network sites that currently collect high quality biospecimens. TCGA TSS awardees will either have an on-site biorepository (located in the same institution as the specimen collection) or demonstrate capability to collect, short-term store, and ship high quality biospecimens to an appropriate biorepository. SAIC-Frederick is hopeful that many sites will meet the qualifications and would find it attractive to participate in the specimen collection portion of TCGA. Proposals shall continue to be accepted on a rolling basis thereafter until the solicitation is amended and closed. Case CCC Clinical Trials Protocol Specific Research Support FundingThe Case CCC is encouraging investigators to submit Letters of Intent for the Protocol Specific Research Support funding for Year 2012. The budgeted funds are for the conduct of early phase clinical trials and restricted to support research nurses and data managers directly involved in the conduct of these clinical trials. Studies developed jointly between UH and CCF with planned accrual at both institutions will be prioritized. Please direct questions and requests for information about the funding process to Katarzyna Karelus, Administrative Director, Case CCC Clinical Research Office, at 216.844.4176 or kxk384@case.edu. | EVENTS
**All events are open to anyone interested in attending January 23Skeletal Research Center Seminar January 24Cancer Biology and Glickman Urological and Kidney Institute: Prostate Cancer Endowed Chair Candidate Seminar Immunology Seminar Series CFAR Leaders in AIDS Seminar January 25Hematology and Oncology Division Research Conference Genomics Informational Tour January 26Molecular Biology and Microbiology Seminar NCRM Monthly Seminar January 27Hem/Onc Fellows Conference Taussig Cancer Institute Grand Rounds Cell Biology Seminar Series Cancer Center Seminar Series Cancer Center Research in Progress Seminar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTSPathology Research Seminar Cancer Cell Signaling Program Retreat ADDITIONAL UPCOMING SEMINARS & EVENTSDepartment of Biomedical Engineering Special Seminar NCI Second Symposium on Translational Genomics |
|
|
|
PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES |
|
|
Children's Tumor Foundation Young Investigator Award Program |
Leukemia & Lymphoma Society Translational Research Program |
|
|
|
NIH BULLETIN – Notices and Funding OpportunitiesBiomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R01)(PA-12-082) Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R21)(PA-12-083) Notice of Legislative Mandates in Effect for FY2012 (NOT-OD-12-034) Notice of Salary Limitation on Grants, Cooperative Agreements, and Contracts (NOT-OD-12-035) |
|
| Produced by: Gillian Irwin Todd 11100 Euclid Avenue, Wearn 149 Cleveland, Ohio 44106-5065 216-844-8317 phone 216-844-7832 fax gillian.irwin@case.edu |
HELP US HELP YOU!If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to gillian.irwin@case.edu. |
|
|